Artelo Biosciences, Inc. (ARTL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ARTL Stock Price Chart Interactive Chart >
ARTL Price/Volume Stats
| Current price | $3.06 | 52-week high | $11.07 |
| Prev. close | $3.07 | 52-week low | $2.38 |
| Day low | $2.95 | Volume | 29,321 |
| Day high | $3.08 | Avg. volume | 27,613 |
| 50-day MA | $2.96 | Dividend yield | N/A |
| 200-day MA | $3.99 | Market Cap | 8.74M |
Artelo Biosciences, Inc. (ARTL) Company Bio
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.
Latest ARTL News From Around the Web
Below are the latest news stories about ARTELO BIOSCIENCES INC that investors may wish to consider to help them evaluate ARTL as an investment opportunity.
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossExpects to Commence Phase 2a of CAReS During the First Quarter of 2023SOLANA BEACH, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that enrollment in the final cohort of the Phase 1b stage of its Cancer Appetite Recovery Study (CAReS) is now complete. The first stage of th |
Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2ndCEO Gregory Gorgas to discuss developments related to the Company’s Cancer Appetite Recovery Study (CAReS) Presentation on Thursday, February 2, 2023 at 1:00 PM ET SOLANA BEACH, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced today that Gregory D. Gorgas, Chief Executive Officer |
Maxim Group Reaffirms Their Buy Rating on Artelo Biosciences (ARTL)In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Artelo Biosciences (ARTL - Research Report), with a price target of $10.00. The company's shares opened today at $2.68.According to TipRanks, McCarthy is an analyst with an average return of -38.9% and a 13.96% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Immutep, Actinium Pharmaceuticals, and SCYNEXIS.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Artelo Biosciences with a $41.67 average price target, a 1,454.85% upside from current levels. In a report released yesterday, Ladenburg Thalmann & Co. |
Ladenburg Thalmann & Co. Keeps Their Buy Rating on Artelo Biosciences (ARTL)In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Artelo Biosciences (ARTL - Research Report), with a price target of $60.00. The company's shares closed yesterday at $2.87.According to TipRanks, Higgins is a 3-star analyst with an average return of 2.9% and a 28.57% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Palatin Technologies, Eiger Biopharmaceuticals, and Marinus.Artelo Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $41.67, which is a 1,351.92% upside from current levels. In a report released today, H.C. |
Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business UpdateEnrollment of Phase 2a CAReS Study Expected to Commence Near Year-End |
ARTL Price Returns
| 1-mo | -2.55% |
| 3-mo | 6.62% |
| 6-mo | -23.50% |
| 1-year | -50.24% |
| 3-year | -89.90% |
| 5-year | N/A |
| YTD | 5.88% |
| 2022 | -62.88% |
| 2021 | -28.90% |
| 2020 | -72.96% |
| 2019 | -60.87% |
| 2018 | N/A |
Loading social stream, please wait...